NASDAQ:ABMD - Abiomed Stock Price, Price Target & More

$305.70 -1.93 (-0.63 %)
(As of 04/19/2018 03:18 PM ET)
Previous Close$307.63
Today's Range$303.51 - $307.05
52-Week Range$122.60 - $309.28
Volume240,738 shs
Average Volume415,947 shs
Market Capitalization$13.48 billion
P/E Ratio261.28
Dividend YieldN/A
Beta0.17

About Abiomed (NASDAQ:ABMD)

Abiomed logoABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. It also manufactures and sells AB5000 circulatory support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, the company engages in the research, development, prototyping, and the pre-serial production of a percutaneous expandable catheter pump, which enhances blood circulation from the heart with an external drive shaft. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ABMD
CUSIP00365410
Phone978-646-1400

Debt

Debt-to-Equity RatioN/A
Current Ratio5.60%
Quick Ratio4.98%

Price-To-Earnings

Trailing P/E Ratio261.28
Forward P/E Ratio135.87
P/E Growth2.99

Sales & Book Value

Annual Sales$445.30 million
Price / Sales30.40
Cash Flow$1.3450 per share
Price / Cash227.29
Book Value$10.38 per share
Price / Book29.45

Profitability

EPS (Most Recent Fiscal Year)$1.17
Net Income$52.11 million
Net Margins16.58%
Return on Equity15.54%
Return on Assets13.40%

Miscellaneous

Employees908
Outstanding Shares44,280,000

How to Become a New Pot Stock Millionaire

Abiomed (NASDAQ:ABMD) Frequently Asked Questions

What is Abiomed's stock symbol?

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

How were Abiomed's earnings last quarter?

Abiomed (NASDAQ:ABMD) issued its earnings results on Thursday, February, 1st. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.20. The medical equipment provider earned $154 million during the quarter, compared to analysts' expectations of $154 million. Abiomed had a net margin of 16.58% and a return on equity of 15.54%. The company's revenue for the quarter was up 34.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.34 EPS. View Abiomed's Earnings History.

When is Abiomed's next earnings date?

Abiomed is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Abiomed.

What price target have analysts set for ABMD?

9 brokers have issued 12 month price objectives for Abiomed's shares. Their forecasts range from $259.00 to $370.00. On average, they anticipate Abiomed's stock price to reach $305.8571 in the next year. View Analyst Ratings for Abiomed.

Who are some of Abiomed's key competitors?

Who are Abiomed's key executives?

Abiomed's management team includes the folowing people:
  • Mr. Michael R. Minogue, Chairman, Chief Exec. Officer and Pres (Age 51)
  • Dr. David M. Weber Ph.D., Chief Operating Officer (Age 57)
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 54)
  • Mr. William J. Bolt, Sr. VP of Global Quality, Regulatory & Clinical Operations (Age 66)
  • Dr. Thorsten Siess, Chief Technology Officer

Has Abiomed been receiving favorable news coverage?

News articles about ABMD stock have trended somewhat negative on Thursday, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Abiomed earned a media sentiment score of -0.03 on Accern's scale. They also assigned media headlines about the medical equipment provider an impact score of 47.01 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Abiomed's major shareholders?

Abiomed's stock is owned by a variety of of institutional and retail investors. Top institutional investors include PRIMECAP MANAGEMENT COMPANY (9.23%) and PRIMECAP MANAGEMENT COMPANY (9.23%). Company insiders that own Abiomed stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley, Michael R Minogue and Paul Thomas. View Institutional Ownership Trends for Abiomed.

How do I buy shares of Abiomed?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abiomed's stock price today?

One share of ABMD stock can currently be purchased for approximately $305.70.

How big of a company is Abiomed?

Abiomed has a market capitalization of $13.48 billion and generates $445.30 million in revenue each year. The medical equipment provider earns $52.11 million in net income (profit) each year or $1.17 on an earnings per share basis. Abiomed employs 908 workers across the globe.

How can I contact Abiomed?

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]


MarketBeat Community Rating for Abiomed (ABMD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  321 (Vote Outperform)
Underperform Votes:  250 (Vote Underperform)
Total Votes:  571
MarketBeat's community ratings are surveys of what our community members think about Abiomed and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Abiomed (NASDAQ:ABMD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Abiomed in the last 12 months. Their average twelve-month price target is $305.8571, suggesting that the stock has a possible upside of 0.05%. The high price target for ABMD is $370.00 and the low price target for ABMD is $259.00. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.782.752.712.75
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $305.8571$301.50$210.00$174.7143
Price Target Upside: 0.05% upside12.61% upside7.03% downside0.50% upside

Abiomed (NASDAQ:ABMD) Consensus Price Target History

Price Target History for Abiomed (NASDAQ:ABMD)

Abiomed (NASDAQ:ABMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2018Goldman SachsInitiated CoverageBuy -> Buy$332.00MediumView Rating Details
2/16/2018SunTrust BanksReiterated RatingBuy$370.00N/AView Rating Details
2/4/2018BTIG ResearchReiterated RatingHoldHighView Rating Details
2/2/2018Leerink SwannBoost Price TargetOutperform$300.00LowView Rating Details
2/2/2018Morgan StanleyBoost Price TargetEqual Weight -> Equal Weight$204.00 -> $259.00LowView Rating Details
2/2/2018GuggenheimReiterated RatingBuy$280.00MediumView Rating Details
2/1/2018Jefferies GroupReiterated RatingBuy$300.00MediumView Rating Details
2/1/2018Piper JaffrayReiterated RatingOverweight -> Positive$220.00 -> $300.00MediumView Rating Details
6/8/2017William BlairReiterated RatingOutperform -> OutperformLowView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Abiomed (NASDAQ:ABMD) Earnings History and Estimates Chart

Earnings by Quarter for Abiomed (NASDAQ:ABMD)

Abiomed (NASDAQ:ABMD) Earnings Estimates

2018 EPS Consensus Estimate: $1.86
2019 EPS Consensus Estimate: $2.72
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.40$0.43$0.41
Q2 20183$0.32$0.38$0.35
Q3 20183$0.46$0.58$0.50
Q4 20183$0.52$0.66$0.60
Q1 20192$0.58$0.68$0.63
Q2 20192$0.66$0.68$0.67
Q3 20191$0.62$0.62$0.62
Q4 20192$0.78$0.82$0.80

Abiomed (NASDAQ ABMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018$0.56N/AView Earnings Details
2/1/2018Q3 2018$0.50$0.70$154.00 million$154.00 millionViewN/AView Earnings Details
10/26/2017Q2 2018$0.38$0.54$131.18 million$132.80 millionViewN/AView Earnings Details
7/27/2017Q1 2018$0.42$0.45$130.83 million$132.47 millionViewN/AView Earnings Details
5/4/2017Q4 2017$0.33$0.33$122.82 million$124.68 millionViewListenView Earnings Details
1/26/2017Q317$0.29$0.34$112.71 million$114.70 millionViewListenView Earnings Details
10/27/2016Q217$0.24$0.20$103.16 million$103.00 millionViewListenView Earnings Details
7/28/2016Q117$0.23$0.29$97.23 million$103.00 millionViewListenView Earnings Details
5/3/2016Q416$0.19$0.24$90.52 million$94.00 millionViewN/AView Earnings Details
2/4/2016Q316$0.15$0.23$80.04 million$85.80 millionViewListenView Earnings Details
10/29/2015Q2$0.13$0.17$74.56 million$76.30 millionViewListenView Earnings Details
8/4/2015Q116$0.08$0.20$66.27 million$73.40 millionViewN/AView Earnings Details
5/5/2015Q415$0.12$0.28$62.55 million$67.60 millionViewN/AView Earnings Details
1/27/2015Q315$0.03$0.30$53.20 million$62.00 millionViewN/AView Earnings Details
10/30/2014Q215$0.02$0.09$48.80 million$51.80 millionViewN/AView Earnings Details
7/31/2014Q115$0.02($0.04)$297.10 million$48.80 millionViewN/AView Earnings Details
5/1/2014Q414$0.09$0.09$50.93 million$50.40 millionViewN/AView Earnings Details
1/31/2014Q314$0.05$0.11$46.00 million$46.20 millionViewN/AView Earnings Details
11/6/2013Q214$0.03$0.03$43.75 million$44.30 millionViewN/AView Earnings Details
8/1/2013Q1 2014$0.06($0.04)$42.93 million$42.70 millionViewN/AView Earnings Details
5/2/2013Q4 2013$0.08$0.09$41.87 million$43.70 millionViewN/AView Earnings Details
2/6/2013Q3 2013$0.07$0.07$38.04 million$38.30 millionViewN/AView Earnings Details
11/1/2012Q213$0.05$0.20$37.47 million$37.40 millionViewN/AView Earnings Details
8/2/2012$0.10$0.16ViewN/AView Earnings Details
5/16/2012$0.07$0.07ViewN/AView Earnings Details
2/3/2012($0.01)$0.07ViewN/AView Earnings Details
11/3/2011($0.09)$0.02ViewN/AView Earnings Details
8/4/2011($0.06)($0.03)ViewN/AView Earnings Details
5/18/2011($0.04)($0.05)ViewN/AView Earnings Details
2/3/2011($0.09)($0.02)ViewN/AView Earnings Details
11/4/2010Q2 2011($0.14)($0.09)ViewN/AView Earnings Details
8/4/2010Q1 2011($0.14)($0.14)ViewN/AView Earnings Details
5/19/2010Q4 2010($0.12)($0.11)ViewN/AView Earnings Details
2/4/2010Q3 2010($0.18)($0.11)ViewN/AView Earnings Details
11/5/2009Q2 2010($0.21)($0.21)ViewN/AView Earnings Details
8/6/2009Q1 2010($0.20)($0.20)ViewN/AView Earnings Details
5/12/2009Q4 2009($0.17)($0.22)ViewN/AView Earnings Details
2/5/2009Q3 2009($0.17)($0.20)ViewN/AView Earnings Details
11/10/2008Q2 2009($0.21)($0.18)ViewN/AView Earnings Details
8/7/2008Q1 2009($0.21)($0.28)ViewN/AView Earnings Details
5/21/2008Q4 2008($0.19)($0.25)ViewN/AView Earnings Details
2/7/2008Q3 2008($0.20)($0.26)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Abiomed (NASDAQ:ABMD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Abiomed (NASDAQ ABMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.00%
Institutional Ownership Percentage: 88.41%
Insider Trading History for Abiomed (NASDAQ:ABMD)
Institutional Ownership by Quarter for Abiomed (NASDAQ:ABMD)

Abiomed (NASDAQ ABMD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/20/2018Andrew J GreenfieldVPSell20,000$270.36$5,407,200.00View SEC Filing  
10/30/2017Dorothy E PuhyDirectorSell6,364$179.08$1,139,665.1239,532View SEC Filing  
10/30/2017Michael G HowleyVPSell10,000$178.64$1,786,400.0056,757View SEC Filing  
10/2/2017Andrew J GreenfieldVPSell11,282$169.32$1,910,268.24View SEC Filing  
8/30/2017Eric A Md RoseDirectorSell982$145.17$142,556.9413,634View SEC Filing  
8/24/2017Eric A Md RoseDirectorSell23,018$151.09$3,477,789.6224,652View SEC Filing  
8/15/2017Paul ThomasDirectorSell10,000$154.71$1,547,100.0012,172View SEC Filing  
7/31/2017David M WeberCOOSell16,500$147.63$2,435,895.00125,122View SEC Filing  
5/16/2017Michael G HowleyVPSell18,279$133.56$2,441,343.2462,105View SEC Filing  
5/8/2017David M WeberCOOSell21,250$130.89$2,781,412.50123,771View SEC Filing  
5/8/2017Dorothy E PuhyDirectorSell13,500$131.12$1,770,120.0038,249View SEC Filing  
5/8/2017Michael G HowleyVPSell600$132.84$79,704.0048,305View SEC Filing  
3/17/2017Andrew J GreenfieldVPSell10,000$124.00$1,240,000.0066,307View SEC Filing  
12/13/2016Dorothy E PuhyDirectorSell8,000$120.00$960,000.0032,749View SEC Filing  
11/30/2016Eric A Md RoseDirectorSell8,000$110.81$886,480.0021,259View SEC Filing  
9/22/2016Michael R MinogueCEOSell28,039$127.07$3,562,915.73215,488View SEC Filing  
9/21/2016Michael R MinogueCEOSell5,034$127.07$639,670.38215,782View SEC Filing  
9/19/2016Michael R MinogueCEOSell58,710$127.00$7,456,170.00215,782View SEC Filing  
8/15/2016Dorothy E PuhyDirectorSell5,160$123.94$639,530.4024,749View SEC Filing  
8/10/2016Dorothy E PuhyDirectorSell3,900$122.31$477,009.0033,811View SEC Filing  
8/8/2016Michael G HowleyVPSell17,853$119.20$2,128,077.6065,558View SEC Filing  
8/1/2016Henri A TermeerDirectorSell25,866$118.70$3,070,294.20325,778View SEC Filing  
6/29/2016Michael G HowleyVPSell10,000$106.58$1,065,800.0065,558View SEC Filing  
6/7/2016Andrew J GreenfieldVPSell9,000$104.16$937,440.0065,234View SEC Filing  
5/23/2016David M WeberCOOSell4,342$96.97$421,043.74100,159View SEC Filing  
5/16/2016David M WeberCOOSell5,604$94.56$529,914.24116,783View SEC Filing  
5/6/2016David M WeberCOOSell2,145$93.82$201,243.90117,411View SEC Filing  
5/5/2016David M WeberCOOSell52,000$95.27$4,954,040.00121,676View SEC Filing  
5/5/2016Paul ThomasDirectorSell7,500$95.14$713,550.0028,811View SEC Filing  
4/18/2016Andrew J GreenfieldVPSell10,000$99.10$991,000.0061,186View SEC Filing  
4/13/2016Michael G HowleyVPSell9,800$98.64$966,672.0062,268View SEC Filing  
4/8/2016Michael G HowleyVPSell200$98.80$19,760.0052,668View SEC Filing  
4/1/2016Dorothy E PuhyDirectorSell10,000$95.02$950,200.0047,792View SEC Filing  
3/31/2016Andrew J GreenfieldVPSell15,000$94.11$1,411,650.0058,941View SEC Filing  
3/24/2016David M WeberCOOSell5,235$89.93$470,783.55113,411View SEC Filing  
3/22/2016Andrew J GreenfieldVPSell24,800$89.06$2,208,688.0073,614View SEC Filing  
3/22/2016Dorothy E PuhyDirectorSell10,000$90.30$903,000.0052,190View SEC Filing  
3/21/2016Andrew J GreenfieldVPSell19,572$89.07$1,743,278.0473,614View SEC Filing  
3/10/2016Andrew J GreenfieldVPSell200$89.00$17,800.0054,242View SEC Filing  
3/8/2016David M WeberCOOSell17,521$85.20$1,492,789.20125,761View SEC Filing  
3/8/2016William J BoltSVPSell17,510$85.19$1,491,676.9098,392View SEC Filing  
3/7/2016David M WeberCOOSell8,111$85.21$691,138.31125,761View SEC Filing  
3/7/2016Dorothy E PuhyDirectorSell4,000$85.00$340,000.0066,190View SEC Filing  
3/7/2016William J BoltSVPSell7,987$85.20$680,492.4098,392View SEC Filing  
2/8/2016Dorothy E. PuhyDirectorSell4,000$80.47$321,880.0062,190View SEC Filing  
8/19/2015Michael R. MinogueCEOSell146,800$104.87$15,394,916.00239,718View SEC Filing  
8/17/2015Dorothy E PuhyDirectorSell2,580$103.91$268,087.80View SEC Filing  
8/14/2015Dorothy E PuhyDirectorSell2,580$105.27$271,596.60View SEC Filing  
7/17/2015Michael G HowleyVPSell21,295$70.00$1,490,650.00View SEC Filing  
6/15/2015Andrew J GreenfieldVPSell3,185$65.00$207,025.00View SEC Filing  
5/29/2015Martin P SutterDirectorBuy7,500$60.17$451,275.00View SEC Filing  
5/27/2015David M WeberCOOSell17,968$60.77$1,091,915.36View SEC Filing  
5/12/2015Michael G HowleyVPSell17,353$66.47$1,153,453.91View SEC Filing  
5/7/2015Andrew J GreenfieldVPSell3,500$71.00$248,500.00View SEC Filing  
5/7/2015Robert BowenCFOSell2,372$71.52$169,645.44View SEC Filing  
5/6/2015David M WeberCOOSell1,605$73.72$118,320.60View SEC Filing  
5/6/2015Michael R MinogueCEOSell8,840$73.12$646,380.80View SEC Filing  
5/6/2015William J BoltSVPSell1,750$74.27$129,972.50View SEC Filing  
3/23/2015David M WeberCOOSell3,765$71.08$267,616.20View SEC Filing  
10/31/2014Andrew J GreenfieldVPSell15,000$31.90$478,500.00View SEC Filing  
10/31/2014Michael R MinogueCEOSell164,000$31.14$5,106,960.00View SEC Filing  
7/28/2014Michael R MinogueCEOSell82,383$26.30$2,166,672.90View SEC Filing  
5/27/2014Andrew J GreenfieldVPSell7,026$21.10$148,248.60View SEC Filing  
5/27/2014David M WeberCOOSell10,172$21.11$214,730.92View SEC Filing  
5/27/2014Michael R MinogueCEOSell90,001$21.19$1,907,121.19View SEC Filing  
5/27/2014Robert BowenCFOSell6,820$21.11$143,970.20View SEC Filing  
5/27/2014William J BoltSVPSell8,029$21.10$169,411.90View SEC Filing  
5/15/2014David WeberCOOSell1,425$20.94$29,839.50130,482View SEC Filing  
5/15/2014Michael HowleyVPSell1,267$20.94$26,530.9874,486View SEC Filing  
5/15/2014Michael MinogueCEOSell4,433$20.94$92,827.02260,912View SEC Filing  
5/15/2014William BoltSVPSell1,110$20.94$23,243.4094,205View SEC Filing  
1/10/2014Robert BowenCFOSell37,500$30.00$1,125,000.0066,929View SEC Filing  
9/3/2013David WeberCOOSell6,500$24.00$156,000.00126,907View SEC Filing  
9/3/2013William BoltSVPSell20,000$24.00$480,000.0089,718View SEC Filing  
8/14/2013William BoltSVPSell21,534$23.35$502,818.9089,718View SEC Filing  
8/13/2013David WeberCOOSell4,400$23.00$101,200.00133,407View SEC Filing  
8/13/2013Michael HowleyVPSell8,400$23.00$193,200.0068,753View SEC Filing  
8/5/2013David WeberCOOSell7,100$22.90$162,590.00137,807View SEC Filing  
8/5/2013Michael HowleyVPSell1,600$23.03$36,848.0077,153View SEC Filing  
8/5/2013Robert BowenCFOSell2,235$22.64$50,600.4066,929View SEC Filing  
8/5/2013W Gerald AustenDirectorSell8,000$22.85$182,800.00View SEC Filing  
8/5/2013William BoltSVPSell20,166$22.70$457,768.2098,552View SEC Filing  
7/31/2013Michael R MinogueCEOSell36,500$25.04$913,960.00View SEC Filing  
7/17/2013Michael G HowleyVPSell10,000$24.45$244,500.00View SEC Filing  
7/15/2013Robert BowenCFOSell40,786$23.50$958,471.00View SEC Filing  
7/11/2013Robert BowenCFOSell1,499$23.50$35,226.50View SEC Filing  
6/4/2013David M WeberCOOSell6,519$21.20$138,202.80View SEC Filing  
6/4/2013Michael G HowleyVPSell3,881$21.20$82,277.20View SEC Filing  
6/4/2013Michael R MinogueCEOSell17,667$21.23$375,070.41View SEC Filing  
6/4/2013Robert BowenCFOSell5,298$21.20$112,317.60View SEC Filing  
6/4/2013William J BoltSVPSell4,967$21.20$105,300.40View SEC Filing  
5/29/2013Michael R MinogueCEOSell58,833$21.83$1,284,324.39View SEC Filing  
5/28/2013David M WeberCOOSell6,018$22.18$133,479.24View SEC Filing  
5/28/2013Michael G HowleyVPSell5,476$22.18$121,457.68View SEC Filing  
5/28/2013Robert BowenCFOSell5,102$22.18$113,162.36View SEC Filing  
5/28/2013William J BoltSVPSell4,629$22.18$102,671.22View SEC Filing  
5/23/2013Andrew J GreenfieldVPSell1,666$21.63$36,035.58View SEC Filing  
5/23/2013Michael R MinogueCEOSell5,666$21.62$122,498.92View SEC Filing  
5/17/2013Robert BowenCFOSell2,715$23.50$63,802.50View SEC Filing  
5/9/2013Michael R MinogueCEOSell20,000$21.00$420,000.00View SEC Filing  
5/7/2013Henri A TermeerDirectorBuy100,000$19.86$1,986,000.00View SEC Filing  
2/25/2013Henri A TermeerDirectorBuy100,000$14.98$1,498,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Abiomed (NASDAQ ABMD) News Headlines

Source:
DateHeadline
Can Neurotechnology & Spine Drive Stryker (SYK) Q1 Earnings?Can Neurotechnology & Spine Drive Stryker (SYK) Q1 Earnings?
finance.yahoo.com - April 17 at 9:52 AM
Abiomed (ABMD) Downgraded to "Hold" at BidaskClubAbiomed (ABMD) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - April 16 at 12:02 PM
Abiomed (ABMD) Expected to Announce Quarterly Sales of $163.84 MillionAbiomed (ABMD) Expected to Announce Quarterly Sales of $163.84 Million
www.americanbankingnews.com - April 14 at 4:17 AM
Artificial Organs Global Market Forecast to 2023 - Market Projected to Reach $21 Billion Growing at a CAGR of 9.5%Artificial Organs Global Market Forecast to 2023 - Market Projected to Reach $21 Billion Growing at a CAGR of 9.5%
www.prnewswire.com - April 13 at 10:04 AM
Abiomed Fourth Quarter Fiscal 2018 Earnings and Conference Call NotificationAbiomed Fourth Quarter Fiscal 2018 Earnings and Conference Call Notification
finance.yahoo.com - April 13 at 10:04 AM
Quick Profits In This Swing Trade Were Fueled By Stock Market RallyQuick Profits In This Swing Trade Were Fueled By Stock Market Rally
finance.yahoo.com - April 13 at 10:04 AM
Global Artificial Organs Market 2018-2023 with Key Players Abiomed, Heartware, Edwards Lifesciences Corp, Boston ...Global Artificial Organs Market 2018-2023 with Key Players Abiomed, Heartware, Edwards Lifesciences Corp, Boston ...
www.businesswire.com - April 12 at 4:19 PM
$0.64 Earnings Per Share Expected for Abiomed (ABMD) This Quarter$0.64 Earnings Per Share Expected for Abiomed (ABMD) This Quarter
www.americanbankingnews.com - April 12 at 9:19 AM
BidaskClub Upgrades Abiomed (ABMD) to "Buy"BidaskClub Upgrades Abiomed (ABMD) to "Buy"
www.americanbankingnews.com - April 10 at 10:30 PM
Quotidian Technical Highlights on Selected Medical Equipment Stocks -- Abbott Laboratories, ABIOMED, Align ...Quotidian Technical Highlights on Selected Medical Equipment Stocks -- Abbott Laboratories, ABIOMED, Align ...
www.prnewswire.com - April 9 at 10:11 AM
UPDATE: ABIOMED (ABMD) PT Raised to $300 at StephensUPDATE: ABIOMED (ABMD) PT Raised to $300 at Stephens
www.streetinsider.com - April 9 at 10:11 AM
ABIOMEDs (ABMD) Impella 5.5 Receives CE Mark in EuropeABIOMED's (ABMD) Impella 5.5 Receives CE Mark in Europe
www.nasdaq.com - April 5 at 4:14 PM
ABIOMED's (ABMD) Impella 5.5 Receives CE Mark in EuropeABIOMED's (ABMD) Impella 5.5 Receives CE Mark in Europe
finance.yahoo.com - April 5 at 4:14 PM
Abiomed Announces European Approval (CE Marking) for Impella 5.5(TM) and First Patient Treated at University Heart ...Abiomed Announces European Approval (CE Marking) for Impella 5.5(TM) and First Patient Treated at University Heart ...
www.nasdaq.com - April 5 at 8:50 AM
Abiomed Announces European Approval (CE Marking) for Impella 5.5(TM) and First Patient Treated at University Heart Center HamburgAbiomed Announces European Approval (CE Marking) for Impella 5.5(TM) and First Patient Treated at University Heart Center Hamburg
finance.yahoo.com - April 5 at 8:50 AM
Heres Why You Should Invest in ABIOMED (ABMD) Right NowHere's Why You Should Invest in ABIOMED (ABMD) Right Now
www.nasdaq.com - April 4 at 5:14 PM
The 3 Most Expensive Large Healthcare Stocks on the Market: Are They Worth Their Hefty Price Tags?The 3 Most Expensive Large Healthcare Stocks on the Market: Are They Worth Their Hefty Price Tags?
www.fool.com - April 4 at 5:14 PM
Abiomed Announces European Approval (CE Marking) for Impella 5.5™ and First Patient Treated at University Heart ...Abiomed Announces European Approval (CE Marking) for Impella 5.5™ and First Patient Treated at University Heart ...
globenewswire.com - April 4 at 5:14 PM
ABIOMED (ABMD) Research Coverage Started at Goldman SachsABIOMED (ABMD) Research Coverage Started at Goldman Sachs
www.americanbankingnews.com - April 4 at 8:04 AM
Zacks Investment Research Upgrades ABIOMED (ABMD) to "Buy"Zacks Investment Research Upgrades ABIOMED (ABMD) to "Buy"
www.americanbankingnews.com - April 4 at 12:34 AM
ABIOMED (ABMD) Stock Rating Upgraded by ValuEngineABIOMED (ABMD) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 3 at 8:12 PM
FDA Nod for Abiomed Impella CP with SmartAssist Widens SuiteFDA Nod for Abiomed Impella CP with SmartAssist Widens Suite
finance.yahoo.com - April 3 at 4:22 PM
ABIOMED (ABMD) Upgraded by Zacks Investment Research to "Strong-Buy"ABIOMED (ABMD) Upgraded by Zacks Investment Research to "Strong-Buy"
www.americanbankingnews.com - April 3 at 10:07 AM
ABIOMED, Inc. (ABMD) Receives Consensus Rating of "Buy" from BrokeragesABIOMED, Inc. (ABMD) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 31 at 8:11 AM
ABIOMEDs (ABMD) Buy Rating Reaffirmed at Piper JaffrayABIOMED's (ABMD) Buy Rating Reaffirmed at Piper Jaffray
www.americanbankingnews.com - March 30 at 4:32 PM
BRIEF-Abiomed To Appoint Todd Trapp Chief Financial OfficerBRIEF-Abiomed To Appoint Todd Trapp Chief Financial Officer
www.reuters.com - March 30 at 9:53 AM
Abiomed to Appoint New Chief Financial Officer Todd A. TrappAbiomed to Appoint New Chief Financial Officer Todd A. Trapp
finance.yahoo.com - March 30 at 9:53 AM
Watts Water CFO to leave for new opportunity at AbiomedWatts Water CFO to leave for 'new opportunity' at Abiomed
finance.yahoo.com - March 30 at 9:53 AM
ABIOMED (ABMD) Raised to Buy at BidaskClubABIOMED (ABMD) Raised to Buy at BidaskClub
www.americanbankingnews.com - March 28 at 9:48 PM
 Analysts Anticipate ABIOMED, Inc. (ABMD) Will Announce Quarterly Sales of $163.84 Million Analysts Anticipate ABIOMED, Inc. (ABMD) Will Announce Quarterly Sales of $163.84 Million
www.americanbankingnews.com - March 28 at 9:25 AM
Lawsuit: Abiomed fired exec to avoid huge stock payoutLawsuit: Abiomed fired exec to avoid huge stock payout
www.bizjournals.com - March 26 at 4:19 PM
$0.64 Earnings Per Share Expected for ABIOMED, Inc. (ABMD) This Quarter$0.64 Earnings Per Share Expected for ABIOMED, Inc. (ABMD) This Quarter
www.americanbankingnews.com - March 26 at 11:14 AM
ABIOMED (ABMD) and Cogentix Medical (CGNT) Financial ContrastABIOMED (ABMD) and Cogentix Medical (CGNT) Financial Contrast
www.americanbankingnews.com - March 23 at 5:16 AM
MDY, SIVB, TTWO, ABMD: Large Outflows Detected at ETF - NasdaqMDY, SIVB, TTWO, ABMD: Large Outflows Detected at ETF - Nasdaq
www.nasdaq.com - March 21 at 4:25 PM
ABIOMED (ABMD) Banks on Impella Platform, Competition RifeABIOMED (ABMD) Banks on Impella Platform, Competition Rife
finance.yahoo.com - March 13 at 11:24 AM
 Analysts Anticipate ABIOMED, Inc. (ABMD) Will Post Quarterly Sales of $163.84 Million Analysts Anticipate ABIOMED, Inc. (ABMD) Will Post Quarterly Sales of $163.84 Million
www.americanbankingnews.com - March 11 at 8:50 AM
Is It Too Late To Buy ABIOMED Inc (NASDAQ:ABMD)?Is It Too Late To Buy ABIOMED Inc (NASDAQ:ABMD)?
finance.yahoo.com - March 10 at 10:43 AM
Feds say heart pump maker Abiomed wooed doctors with lavish meals, boozeFeds say heart pump maker Abiomed wooed doctors with 'lavish' meals, booze
finance.yahoo.com - March 8 at 4:22 PM
Abiomed to pay $3.1 mln to settle case over lavish doctor mealsAbiomed to pay $3.1 mln to settle case over lavish doctor meals
finance.yahoo.com - March 8 at 4:22 PM
Why Abiomed Soared 14.1% In FebruaryWhy Abiomed Soared 14.1% In February
finance.yahoo.com - March 8 at 11:03 AM
ABIOMED, Inc. (ABMD) Receives Consensus Rating of "Buy" from AnalystsABIOMED, Inc. (ABMD) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 6 at 1:38 PM
17,556 Shares in ABIOMED, Inc. (ABMD) Acquired by Arrowstreet Capital Limited Partnership17,556 Shares in ABIOMED, Inc. (ABMD) Acquired by Arrowstreet Capital Limited Partnership
www.americanbankingnews.com - March 6 at 4:34 AM
Sectoral Asset Management Inc Cuts Position in ABIOMED, Inc. (ABMD)Sectoral Asset Management Inc Cuts Position in ABIOMED, Inc. (ABMD)
www.americanbankingnews.com - March 5 at 3:35 PM
USA Financial Portformulas Corp Buys New Holdings in ABIOMED, Inc. (ABMD)USA Financial Portformulas Corp Buys New Holdings in ABIOMED, Inc. (ABMD)
www.americanbankingnews.com - March 5 at 3:04 PM
Abiomed Showcases Impella® Technology that Enables Heart Recovery at ACC with 25 PresentationsAbiomed Showcases Impella® Technology that Enables Heart Recovery at ACC with 25 Presentations
finance.yahoo.com - March 5 at 10:49 AM
ABIOMED, Inc. (ABMD) Holdings Trimmed by Schroder Investment Management GroupABIOMED, Inc. (ABMD) Holdings Trimmed by Schroder Investment Management Group
www.americanbankingnews.com - March 5 at 9:03 AM
ABIOMED, Inc. (ABMD) Shares Bought by UBS Asset Management Americas Inc.ABIOMED, Inc. (ABMD) Shares Bought by UBS Asset Management Americas Inc.
www.americanbankingnews.com - March 4 at 10:46 AM
Maverick Capital Ltd. Invests $6.11 Million in ABIOMED, Inc. (ABMD)Maverick Capital Ltd. Invests $6.11 Million in ABIOMED, Inc. (ABMD)
www.americanbankingnews.com - March 3 at 2:06 PM
Brown Advisory Inc. Cuts Holdings in ABIOMED, Inc. (ABMD)Brown Advisory Inc. Cuts Holdings in ABIOMED, Inc. (ABMD)
www.americanbankingnews.com - March 3 at 4:56 AM
Next Century Growth Investors LLC Sells 20,778 Shares of ABIOMED, Inc. (ABMD)Next Century Growth Investors LLC Sells 20,778 Shares of ABIOMED, Inc. (ABMD)
www.americanbankingnews.com - March 2 at 5:58 PM

SEC Filings

Abiomed (NASDAQ:ABMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Abiomed (NASDAQ:ABMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Abiomed (NASDAQ ABMD) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.